Literature DB >> 17040963

Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.

Frédéric Lavie1, Corinne Miceli-Richard, Marc Ittah, Jérémie Sellam, Jacques-Eric Gottenberg, Xavier Mariette.   

Abstract

BACKGROUND: The cytokine B cell-activating factor of the TNF family (BAFF) is involved in the pathogenesis of autoimmune diseases.
OBJECTIVE: To access changes in serum protein and mRNA levels of BAFF after rituximab treatment.
METHODS: Serum and peripheral blood mononuclear cells (PBMCs) were isolated from five patients (two with lupus, two with Sjögren's syndrome, one with rheumatoid arthritis) before and 12 weeks (range 7-17) after a first course of rituximab infusion. Monocytes and B cells were selected from healthy controls and cocultured for 72 h. BAFF protein and mRNA levels were assessed by ELISA and real-time PCR, respectively.
RESULTS: After rituximab treatment, median serum BAFF protein level and BAFF to actin mRNA ratio in PBMCs significantly increased. In monocytes cocultured with autologous B cells, BAFF protein level decreased, whereas the mRNA level was stable. In one closely monitored patient, the mRNA ratio of BAFF to actin in PBMCs increased later than the BAFF serum level.
CONCLUSIONS: Two distinct mechanisms are probably involved in the increase in BAFF level after B cell depletion: (1) the decrease in its receptors leading to a release of BAFF; (2) a delayed regulation of BAFF mRNA transcription. This could favour the re-emergence of autoreactive B cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17040963      PMCID: PMC1954605          DOI: 10.1136/ard.2006.060772

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

1.  Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis.

Authors:  Soon-Min Tan; Dong Xu; Viktor Roschke; James W Perry; Daniel G Arkfeld; Glenn R Ehresmann; Thi-Sau Migone; David M Hilbert; William Stohl
Journal:  Arthritis Rheum       Date:  2003-04

2.  Synthesis and release of B-lymphocyte stimulator from myeloid cells.

Authors:  B Nardelli; O Belvedere; V Roschke; P A Moore; H S Olsen; T S Migone; S Sosnovtseva; J A Carrell; P Feng; J G Giri; D M Hilbert
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

3.  Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.

Authors:  Joanna Groom; Susan L Kalled; Anne H Cutler; Carl Olson; Stephen A Woodcock; Pascal Schneider; Jurg Tschopp; Teresa G Cachero; Marcel Batten; Julie Wheway; Davide Mauri; Dana Cavill; Tom P Gordon; Charles R Mackay; Fabienne Mackay
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

4.  B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells.

Authors:  Lai Guan Ng; Andrew P R Sutherland; Rebecca Newton; Fang Qian; Teresa G Cachero; Martin L Scott; Jeffrey S Thompson; Julie Wheway; Tatyana Chtanova; Joanna Groom; Ian J Sutton; Cynthia Xin; Stuart G Tangye; Susan L Kalled; Fabienne Mackay; Charles R Mackay
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

5.  B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

Authors:  William Stohl; Samy Metyas; Soon-Min Tan; Gurtej S Cheema; Bonifacia Oamar; Dong Xu; Viktor Roschke; Youmei Wu; Kevin P Baker; David M Hilbert
Journal:  Arthritis Rheum       Date:  2003-12

6.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

7.  TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma.

Authors:  Marcel Batten; Carrie Fletcher; Lai Guan Ng; Joanna Groom; Julie Wheway; Yacine Laâbi; Xiaoguan Xin; Pascal Schneider; Jurg Tschopp; Charles R Mackay; Fabienne Mackay
Journal:  J Immunol       Date:  2004-01-15       Impact factor: 5.422

8.  The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome.

Authors:  X Mariette; S Roux; J Zhang; D Bengoufa; F Lavie; T Zhou; R Kimberly
Journal:  Ann Rheum Dis       Date:  2003-02       Impact factor: 19.103

9.  B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome.

Authors:  Marc Ittah; Corinne Miceli-Richard; Jacques- Eric Gottenberg; Frédéric Lavie; Thierry Lazure; Nathalie Ba; Jérémie Sellam; Christine Lepajolec; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2006-02-28       Impact factor: 5.156

10.  Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.

Authors:  F Mackay; S A Woodcock; P Lawton; C Ambrose; M Baetscher; P Schneider; J Tschopp; J L Browning
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

View more
  62 in total

Review 1.  Topical and systemic medications for the treatment of primary Sjögren's syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Antoni Sisó-Almirall; Xavier Bosch; Athanasios G Tzioufas
Journal:  Nat Rev Rheumatol       Date:  2012-05-01       Impact factor: 20.543

2.  Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.

Authors:  Jérémie Sellam; Corinne Miceli-Richard; Jacques-Eric Gottenberg; Marc Ittah; Frédéric Lavie; Christine Lacabaratz; Nicolas Gestermann; Alexis Proust; Olivier Lambotte; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-12-21       Impact factor: 19.103

3.  Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Whitney S Washel; Nazmim S Bhuiya; Corey S Cutler; Edwin P Alyea; Vincent T Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

Review 4.  B-cell inhibitors as therapy for rheumatoid arthritis: an update.

Authors:  Jennifer Kwan-Morley; Daniel Albert
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

5.  Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma.

Authors:  Stephen M Ansell; Anne J Novak; Steven Ziesmer; Tammy Price-Troska; Betsy LaPlant; Stacey R Dillon; Thomas E Witzig
Journal:  Am J Hematol       Date:  2009-02       Impact factor: 10.047

6.  Role of B cells in common variable immune deficiency.

Authors:  Sam Ahn; Charlotte Cunningham-Rundles
Journal:  Expert Rev Clin Immunol       Date:  2009-09       Impact factor: 4.473

7.  B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia.

Authors:  G Lake-Bakaar; I Jacobson; A Talal
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

Review 8.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

9.  B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.

Authors:  Silvia Bosello; Maria De Santis; Gina Lama; Cristina Spanò; Cristiana Angelucci; Barbara Tolusso; Gigliola Sica; Gianfranco Ferraccioli
Journal:  Arthritis Res Ther       Date:  2010-03-25       Impact factor: 5.156

10.  Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort.

Authors:  Jacques-Eric Gottenberg; Corinne Miceli-Richard; Béatrice Ducot; Philippe Goupille; Bernard Combe; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.